martes, 22 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls

View original at finance.yahoo.com
How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Analysts have shifted their price targets for Halozyme Therapeutics into a $75 to $90 range, even as the model fair value estimate holds steady at $84.5

    60% confidence

  • Benchmark raised Halozyme price target to $90 from $75, citing strong quarterly results and positive forward guidance as key supports for its constructive view

    60% confidence

  • Leerink described the Entyvio ENHANZE deal with Takeda as positive, stressing that management delivered on its commitment to secure a partnership tied to a blockbuster product, even with a lower royalty rate than some past deals

    60% confidence

  • TD Cowen moved Halozyme price target to $90 from $79 and pointed to the value of clear multi year frameworks and multiple potential growth drivers when assessing Halozyme within the broader tools and biotech group

    60% confidence

  • Morgan Stanley lifted Halozyme price target to $94 from $78 after strong Q4 results, highlighting royalty revenues, expanding ENHANZE partnerships, and progress with Hypercon and Surf Bio assets

    60% confidence

  • Wells Fargo raised Halozyme target to $75 from $65 but kept an Equal Weight rating, emphasizing that progress in next generation subcutaneous technologies remains critical for Halozyme's longer term outlook

    60% confidence

  • Leerink pointed out that the Entyvio royalty rate is lower than Halozyme has secured previously and questioned whether payers will support a premium once Entyvio faces biosimilar competition, which could cap the economic upside from that agreement

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,983
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,983 hechos verificados con la fuente5,304 documentos fuente archivados
Consulta estos datos → isubstrate.com
How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls — Source | Via News | es.VIA.NEWS